Toshiaki Iwase1,2, Xiaoping Wang1,2, Tushaar Vishal Shrimanker1,2, Mikhail G Kolonin3, Naoto T Ueno4,5. 1. Section of Translational Breast Cancer Research, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 1354, Houston, TX, 77030, USA. 2. Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA. 3. Center for Metabolic and Degenerative Diseases, The University of Texas Health Science Center at Houston, 7000 Fannin Street, Houston, TX, 77030, USA. 4. Section of Translational Breast Cancer Research, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 1354, Houston, TX, 77030, USA. nueno@mdanderson.org. 5. Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA. nueno@mdanderson.org.
Abstract
PURPOSE: The purpose of this review is to clarify the association of body composition with breast cancer risk and treatment, including physiological mechanisms, and to elucidate strategies for overcoming unfavorable body composition changes that relate to breast cancer progression. METHODS: We have summarized updated knowledge regarding the mechanism of the negative association of altered body composition with breast cancer risk and treatment. We also review strategies for reversing unfavorable body composition based on the latest clinical trial results. RESULTS: Body composition changes in patients with breast cancer typically occur during menopause or as a result of chemotherapy or endocrine therapy. Dysfunction of visceral adipose tissue (VAT) in the setting of obesity underlies insulin resistance and chronic inflammation, which can lead to breast cancer development and progression. Insulin resistance and chronic inflammation are also observed in patients with breast cancer who have sarcopenia or sarcopenic obesity. Nutritional support and a personalized exercise program are the fundamental interventions for reversing unfavorable body composition. Other interventions that have been explored in specific situations include metformin, testosterone, emerging agents that directly target the adipocyte microenvironment, and bariatric surgery. CONCLUSIONS: A better understanding of the biology of body composition phenotypes is key to determining the best intervention program for patients with breast cancer.
PURPOSE: The purpose of this review is to clarify the association of body composition with breast cancer risk and treatment, including physiological mechanisms, and to elucidate strategies for overcoming unfavorable body composition changes that relate to breast cancer progression. METHODS: We have summarized updated knowledge regarding the mechanism of the negative association of altered body composition with breast cancer risk and treatment. We also review strategies for reversing unfavorable body composition based on the latest clinical trial results. RESULTS: Body composition changes in patients with breast cancer typically occur during menopause or as a result of chemotherapy or endocrine therapy. Dysfunction of visceral adipose tissue (VAT) in the setting of obesity underlies insulin resistance and chronic inflammation, which can lead to breast cancer development and progression. Insulin resistance and chronic inflammation are also observed in patients with breast cancer who have sarcopenia or sarcopenic obesity. Nutritional support and a personalized exercise program are the fundamental interventions for reversing unfavorable body composition. Other interventions that have been explored in specific situations include metformin, testosterone, emerging agents that directly target the adipocyte microenvironment, and bariatric surgery. CONCLUSIONS: A better understanding of the biology of body composition phenotypes is key to determining the best intervention program for patients with breast cancer.
Entities:
Keywords:
Body composition; Breast neoplasm; Obesity; Sarcopenia; Skeletal muscle; Visceral adipose tissue
Authors: Laura Baglietto; Gianluca Severi; Dallas R English; Kavitha Krishnan; John L Hopper; Catriona McLean; Howard A Morris; Wayne D Tilley; Graham G Giles Journal: Cancer Epidemiol Biomarkers Prev Date: 2010-01-19 Impact factor: 4.254
Authors: Katherine M Flegal; Deanna Kruszon-Moran; Margaret D Carroll; Cheryl D Fryar; Cynthia L Ogden Journal: JAMA Date: 2016-06-07 Impact factor: 56.272
Authors: Kai-Ming Li; Rosa Todorovic; Prabu Devanesan; Sheila Higginbotham; Harald Köfeler; Ragulan Ramanathan; Michael L Gross; Eleanor G Rogan; Ercole L Cavalieri Journal: Carcinogenesis Date: 2003-10-24 Impact factor: 4.944
Authors: Jennifer K Litton; Ana M Gonzalez-Angulo; Carla L Warneke; Aman U Buzdar; Shu-Wan Kau; Melissa Bondy; Somdat Mahabir; Gabriel N Hortobagyi; Abenaa M Brewster Journal: J Clin Oncol Date: 2008-09-01 Impact factor: 44.544
Authors: Bella Pajares; Marina Pollán; Miguel Martín; John R Mackey; Ana Lluch; Joaquín Gavila; Charles Vogel; Manuel Ruiz-Borrego; Lourdes Calvo; Tadeusz Pienkowski; Álvaro Rodríguez-Lescure; Miguel Angel Seguí; Olivier Tredan; Antonio Antón; Manuel Ramos; María del Carmen Cámara; César Rodríguez-Martín; Eva Carrasco; Emilio Alba Journal: Breast Cancer Res Date: 2013-11-06 Impact factor: 6.466
Authors: Manuel Picon-Ruiz; Cynthia Morata-Tarifa; Janeiro J Valle-Goffin; Eitan R Friedman; Joyce M Slingerland Journal: CA Cancer J Clin Date: 2017-08-01 Impact factor: 508.702
Authors: Bruce A Bunnell; Elizabeth C Martin; Margarite D Matossian; Courtney K Brock; Khoa Nguyen; Bridgette Collins-Burow; Matthew E Burow Journal: Cancer Metastasis Rev Date: 2022-08-24 Impact factor: 9.237